BridgeMD
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
EU CTIS ID: 2025-524001-33-00
What this study is testing
To evaluate the efficacy of IMVT-1402 as assessed by maintenance of euthyroidism, off ATD, and off IMVT-1402 for 52 weeks in Group A Participants
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
You likely can't join if
- Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study
The study team makes the final eligibility decision.
Where it's taking place
- New Zealand
- United States
- Korea, Republic of
- Chile
- Japan
- United Kingdom
- Brazil
- Mexico
- Israel
- Australia
- Georgia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Zealand; United States; Korea, Republic of; Chile; Japan; United Kingdom and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.